Elms United Animal Hospital Group Co., Ltd.
Thank you for reporting the achievement of the number of cases in AIM’s academic joint research and for your cooperation
The results of the AIM research were initially expected, and Dr. Miyazaki is scheduled to announce these results in a paper in the near future.
The Institute for AIM Medicine (Representative Director and Director: Dr. Toru Miyazaki, former professor of the University of Tokyo Graduate School of Medicine, hereinafter referred to as IAM) and Elms United Animal Hospital Group Co., Ltd. (Headquarters: Tokyo) Bunkyo-ku, Tokyo, President: Hiroyuki Arakawa, hereinafter: EUG) will start academic joint research on AIM from April 2022, and have continued to administer AIM to cats with specific stages of kidney disease. However, we would like to report that we have achieved the target number of cases thanks to the cooperation of EUG patients, and we would like to thank the patients for their cooperation.
The results of this research were initially expected, and Dr. Miyazaki is scheduled to publish these results in a paper in the near future. In addition, we would like to report that the joint research between IAM and EUG will proceed to the next step based on this result, and we will continue to make efforts to contribute to the development of veterinary medicine. I shall go.
March 31, 2023
To whom it may concern
General Incorporated Association AIM Medical Research Institute Representative Director / Director Toru Miyazaki
Elms United Animal Hospital Group Co., Ltd.
Hiroyuki Arakawa, President and Representative Director
Thank you for reporting the achievement of the number of cases in AIM’s academic joint research and for your cooperation
(Accompanying termination of AIM administration reception)
The Institute for AIM Medicine (Representative Director and Director: Dr. Toru Miyazaki, former professor of the University of Tokyo Graduate School of Medicine, hereinafter referred to as IAM) and Elms United Animal Hospital Group Co., Ltd. (Headquarters: Tokyo) Bunkyo-ku, Tokyo, President: Hiroyuki Arakawa, hereinafter: EUG) will start academic joint research on AIM from April 2022, and have continued to administer AIM to cats with specific stages of kidney disease. However, we would like to report that we have achieved the target number of cases thanks to the cooperation of EUG patients, and we would like to thank the patients for their cooperation.
The results of this research were initially expected, and Dr. Miyazaki is scheduled to publish these results in a paper in the near future. In addition, we would like to report that the joint research between IAM and EUG will proceed to the next step based on this result, and we will continue to make efforts to contribute to the development of veterinary medicine. I shall go.
Approximately 40% of cats suffer from kidney disease, which is the cause of many deaths, but the mechanism behind this disease remains unknown. From April 2006 to March 2022, Dr. Toru Miyazaki, the representative director and director of IAM, was a professor at the Center for Disease Biology and Biotechnology, Graduate School of Medicine, the University of Tokyo. ) promotes healing in acute kidney injury by removing dead cells that accumulate in the lumen of renal tubules. Furthermore, he published in Scientific Reports that the important cause of the remarkably high incidence of kidney disease in cats is the congenital failure of AIM. was expected to be possible. Under such circumstances, in order to accelerate the completion and practical application of AIM drug discovery, Dr. Miyazaki left the University of Tokyo at the end of March last year to found IAM and assumed the post of Representative Director and Director himself. We have decided to start this joint research (research period of 1 year) with EUG in order to speed up the development of clinical trials of cat drugs, which is one of IAM’s greatest missions.
EUG has MRI, CT, etc., and operates directly operated hospitals + 2 clinics nationwide, centered on general medical centers with highly specialized veterinarians. We have been conducting joint research with IAM to verify the effects of AIM on disease stages as academic research aimed at future clinical trials of AIM drugs. AIM protein will be administered to the owner of a cat in the target stage of this study, who is undergoing treatment for chronic kidney disease, and who understands the purpose of this study and agrees to participate in the study under the informed consent of the EUG. We observed the effect of the product for 6 months and confirmed the expected effect. The trial administration of AIM was conducted at the EUG hospital under the careful supervision of veterinarians, and the data analysis was conducted jointly by IAM and EUG.
It is expected that the survival period of cats as companion animals, which are now part of the family, can be extended by suppressing renal dysfunction and associated uremia symptoms. We would like to aim for early completion of AIM drug discovery through collaboration between IAM and EUG.
■ What is AIM
AIM (apoptosis inhibitor of macrophage) is a blood protein discovered by Dr. Toru Miyazaki and published in the Journal of Experimental Medicine in 1999. AIM is bound to immunoglobulin M (IgM) pentamer, a type of antibody, and is present in the blood at approximately 5 µg (micrograms) per 1 mL. Most AIMs are inactive in the body by binding to IgM. When “waste” such as protein that causes various diseases accumulates in the body, AIM separates from IgM and binds to such waste. Using the AIM bound to this garbage as a landmark, macrophages and other food-eating cells (phagocytic cells) eat and clean up the garbage along with the AIM. In this way, the garbage in the body that causes various diseases is constantly cleaned, and our bodies are protected from getting sick. However, if the amount of AIM you are born with is small, or the AIM does not work, or if you have a sufficient amount of AIM but there is a large amount of garbage that cannot be processed with your own AIM, etc., the garbage will be handled well. It accumulates in the body without being cleaned up, and as a result, various diseases develop and get worse. In other words, whether we are healthy or sick is determined by the conflict between the amount of garbage produced in the body and the ability of AIM and phagocytic cells to clean it up. Therefore, by replenishing the missing AIM, the garbage will be sufficiently cleaned up and many diseases will be prevented from developing, and even if you are already ill, it is possible to stop the progression and start healing. must. Based on this concept, Dr. Miyazaki’s research team has so far proven that AIM can prevent and treat various diseases, including kidney disease and cerebral infarction, and has published many papers. In the future, IAM will be a new disease treatment paradigm that cures many diseases such as kidney disease and cerebral infarction that have no definitive treatment until now, by a simple mechanism of having phagocytic cells clean up the garbage in the body with AIM. In order to establish AIM as an actual therapeutic drug, we will promote drug discovery research and development with the support of public institutions such as the Japan Agency for Medical Research and Development (AMED), companies, and individuals.
■ About AIM Medical Research Institute
The Institute for AIM Medicine (abbreviation: IAM) promotes research on AIM comprehensively and intensively and accelerates the practical application of its results. A research institute founded mainly by Ph.D. Through research activities at IAM, we will establish the concept of “new disease treatment by removing garbage from the body”, which is the basic mechanism of AIM’s work, and achieve the following 4 items in 5 years after its establishment in 2022. Aim to do 1. Approval and marketing of AIM drugs for animals (AIM drugs for cats) 2. Commencement of clinical trials of AIM drugs for humans
3. Approval and marketing of human supplements and pet foods 4. Practical application of diagnostic technology based on AIM In addition, we will promote a wide range of basic and clinical research on AIM, related molecules, and various diseases, and focus on training young researchers.
URL: https://iamaim.jp/
■Profile of Toru Miyazaki, Representative Director and Director of IAM Name: Toru Miyazaki
[Image 1
1986 Graduated from the University of Tokyo School of Medicine. Obtained a doctor’s license and entered the third internal medicine department of the university hospital. After graduate school at Kumamoto University, he became a researcher at Louis Pasteur University in France in 1992, and has a laboratory as a senior researcher at the Basel Institute for Immunology in Switzerland since 1995. Associate professor of immunology at the University of Texas since 2000. Since 2006, he has been a professor at the Department of Molecular Pathophysiology, Center for Disease Biotechnology, Graduate School of Medicine, The University of Tokyo. Since 2010, he has been the representative director and director of AIM Research Institute. A book for the general public that spells out AIM research is “The Day Cats Live to 30” (published by Jiji Press in August 2021).
■ About the Elms United Animal Hospital Group
[Image 2
The Elms United Animal Hospital Group is a group hospital that operates the Elms Animal Medical Center, which provides advanced medical care in one place, and the community-based United Animal Hospital.
We operate directly managed hospitals and 2 clinics across the country, centering on a comprehensive medical center with highly specialized veterinarians and MRI and CT equipment. Depending on the case, we aim to build a support system that provides appropriate treatment even in the region by utilizing AI, etc. at the general medical center and veterinary medicine DX business such as
telemedicine and electronic medical record system. In order to provide the best veterinary medicine for patients, we will establish an advanced medical research institute and work on advanced veterinary medicine research.
In addition, as a CSR, we are promoting the “Save The RED LIST” project, which is an activity to protect endangered species. Since 2017, on Amami Oshima, we have been carrying out activities to raise awareness about the protection of the endangered species Amami rabbit. ・Group hospitals: directly managed hospitals + 2 clinics (3 hospitals in Tokyo, 1 clinic, 2 hospitals in Chiba, 1 hospital in Saitama, 1 hospital in Osaka, 1 hospital in Nara, 1 clinic in Kagoshima) ■Overview of Elms United Animal Hospital Group
Company name: Elms United Animal Hospital Group Co., Ltd.
・Head office: 3-30-11 Koishikawa, Bunkyo-ku, Tokyo 112-0002, 1st floor, Claire Koishikawa
・Tokyo Management Planning Office: 5F, 1-14-4 Kamitakaido,
Suginami-ku, Tokyo 168-0074
・Institute for Advanced Medicine: 2nd floor, 1-14-4 Kamitakaido, Suginami-ku, Tokyo 168-0074
・New Domain Development Department: 6-2-27 Nakanoshima, Kita-ku, Osaka 530-0005 ・Purchasing Department: 2-1-19-1 Hikita-cho, Nara City, Nara Prefecture 631-0843 URL: https://www.elms-united.net
Representative: Hiroyuki Arakawa, Representative Director
Business content
・Operation of advanced veterinary medical center and primary veterinary hospital ・Regenerative medicine, advanced veterinary medicine
・AI-based veterinary medicine/remote medical care ・DX business for veterinary medicine (online consultation, etc.)
Profile of Hiroyuki Arakawa, President and Representative Director (Doctor of Veterinary Medicine)
[Image 3
Born March 31, 1958 in Tokyo. 1983 Graduated from the Faculty of Agriculture, the University of Tokyo, Department of Animal Husbandry and Veterinary Medicine.
1985 Graduated from the Graduate School of Agricultural and Life Sciences. April 1985 Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.), was in charge of pharmacological research at the company’s Tsukuba Research Institute, and experienced management as a technology group leader.
2009-2017 Aiming for the importance of clinical experience, after attending training at the University of Tokyo Animal Medical Center, worked at a private veterinary hospital and worked as director, gaining experience in clinical practice and hospital management. In August 2017, joined the Elms United Animal Hospital Group, which aims to apply advanced medicine to clinical medicine. After that, after serving as the director of Bunkyoin, he assumed the post of representative director from the time the company was established. December 2021 Started academic joint research with Professor Miyazaki (Doctor of Medicine) of the University of Tokyo School of Medicine to verify the therapeutic effects of AIM in cats with kidney disease, and participated as the chief veterinarian.
April 2022 Continued to be in charge of joint research on AIM with AIM Medical Research Institute (one company) established by Dr. Miyazaki. In December 2009, Professor Nobuo Sasaki, former director of the Animal Medical Center of the University of Tokyo, and a veterinarian who was a veterinarian at the same time as a university student, established the NPO Veterinarian Network for Elderly Pet Breeding Support (dissolved in 2021). Since its establishment, he has been active as the secretary general of a non-profit organization that promotes health by raising pets for the elderly (AAT: Animal Assisted Therapy) and supports raising pets for elderly people who have difficulty raising pets. Currently, I am working as a veterinarian and business owner with the aim of contributing to the lives and health of many animals by utilizing advanced veterinary medicine and
regenerative medicine in the research field in clinical veterinary medicine.
[Inquiries regarding this matter]
Elms United Animal Hospital Group Co., Ltd.
Representative Director Hiroyuki Arakawa
E-Mail: arakawa〇elms-united.com (〇 means @)
that’s all
Details about this release:
https://prtimes.jp/main/html/rd/p/000000008.000100614.html
MAIL:cr@prtimes.co.jp